Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Portfolio Pulse from
Immutep's eftilagimod alpha shows promise in treating non-squamous NSCLC patients when combined with KEYTRUDA and chemotherapy, based on positive phase 1 INSIGHT-003 study results. Further data is expected in 2025, with a phase 3 study planned.
November 15, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep's eftilagimod alpha shows positive results in phase 1 study for NSCLC treatment, with further data expected in 2025 and a phase 3 study planned.
The positive results from the phase 1 study suggest potential for eftilagimod alpha as a new treatment standard for NSCLC, which could significantly impact Immutep's market position and stock price. The planned phase 3 study further supports this potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90